Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
•
General Radiation Oncology
•
COVID-19
Are you altering your use of Active Breathing Coordination for breath hold technique patients in light of the COVID-19 pandemic?
Answer from: Radiation Oncologist at Community Practice
We use DIBH, and this has not changed anything in our practice.
Sign In
or
Register
to read more
7092
Related Questions
Given the new ASCO guidelines on SNB in early stage breast cancer, how does the omission of SNB in patients aged 50-70 impact your adjuvant radiation recommendations?
Is DCISionRT appropriate for multifocal DCIS?
Does delay to the time of lumpectomy impact your decision to omit radiation?
Is there any increased risk with adjuvant breast radiation for a patient with muscular dystrophy?
Is there additional concern for late cardiac toxicity when using ultrahypofractionated breast radiation protocols, given that the BED to the heart is higher?
When do you offer adjuvant radiation therapy for a glomus tumor of uncertain malignant potential of the extremity resected with negative margins?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?
Is it appropriate to consider ultra-hypofractionation for phyllodes tumors of the breast when adjuvant radiotherapy is indicated?
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?
Has there been an observed interaction between ACE inhibitors and development of angioedema in a block demarcated superficial radiation therapy treatment volume (ex. lip)?